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A B S T R A C T
Cocaine dependence is a complex psychiatric disorder that is highly comorbid with other psychiatric traits. Twin
and adoption studies suggest that genetic variants contribute substantially to cocaine dependence susceptibility,
which has an estimated heritability of 65–79%. Here we performed a meta-analysis of genome-wide association
studies of cocaine dependence using four datasets from the dbGaP repository (2085 cases and 4293 controls, all
of them selected by their European ancestry). Although no genome-wide significant hits were found in the SNP-
based analysis, the gene-based analysis identified HIST1H2BD as associated with cocaine-dependence (10%
FDR). This gene is located in a region on chromosome 6 enriched in histone-related genes, previously associated
with schizophrenia (SCZ). Furthermore, we performed LD Score regression analysis with comorbid conditions
and found significant genetic correlations between cocaine dependence and SCZ, ADHD, major depressive dis-
order (MDD) and risk taking. We also found, through polygenic risk score analysis, that all tested phenotypes are
significantly associated with cocaine dependence status: SCZ (R2= 2.28%; P=1.21e-26), ADHD (R2= 1.39%;
P=4.5e-17), risk taking (R2= 0.60%; P=2.7e-08), MDD (R2= 1.21%; P=4.35e-15), children's aggressive
behavior (R2= 0.3%; P=8.8e-05) and antisocial behavior (R2= 1.33%; P=2.2e-16). To our knowledge, this
is the largest reported cocaine dependence GWAS meta-analysis in European-ancestry individuals. We identified
suggestive associations in regions that may be related to cocaine dependence and found evidence for shared
genetic risk factors between cocaine dependence and several comorbid psychiatric traits. However, the sample
size is limited and further studies are needed to confirm these results.
1. Introduction
Cocaine is one of the most used illicit drugs worldwide and its abuse
produces serious health problems. In Europe, around 5.2% of adults
(from 15 to 64 years old) have tried cocaine (EMCDDA, 2017), but at
most 20% will develop addiction (Wagner and Anthony, 2002). This
information allows us to estimate the prevalence of cocaine dependence
in the European population around 1.1%, similar to the prevalence
observed in American populations (Compton et al., 2007).
Cocaine dependence is a complex psychiatric disorder that results
from the interaction of environmental and genetic risk factors. It is one
of the most heritable psychiatric conditions, with an estimated herit-
ability of 65–79% (Ducci and Goldman, 2012). Although many case-
control association studies in candidate genes have been performed,
only a few risk variants for cocaine dependence have been identified
and replicated so far, such as rs16969968 in the CHRNA5 gene, en-
coding the cholinergic receptor nicotinic alpha 5 subunit, and rs806368
in CNR1, coding for the cannabinoid receptor 1 (Bühler et al., 2015). To
date, only one genome-wide association study (GWAS) on cocaine de-
pendence has been performed in European- and African-American in-
dividuals (Gelernter et al., 2014). When combining the two popula-
tions, one genome-wide finding was identified in the FAM53B gene,
using a symptom count approach, but this hit could not be replicated in
a subsequent study (Pineda-Cirera et al., 2018).
Several studies have shown that substance use disorders (SUD), and
especially cocaine dependence, is highly comorbid with other
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psychiatric disorders and related phenotypes like aggressive, antisocial
or risk-taking behaviors (Bezinović and Malatestinić, 2009; Hasin and
Kilcoyne, 2012). For example, the occurrence of lifetime SUD in pa-
tients with schizophrenia (SCZ) is 70–80%, in attention deficit/hyper-
activity disorder (ADHD) it is 39.2% and in major depressive disorder
(MDD) it is 16.1% (Currie et al., 2005; Piñeiro-Dieguez et al., 2016;
Westermeyer, 2006). Conversely, about 81% of substance abuse/de-
pendence patients have at least one comorbid mental disorder: 33%
MDD, 11% SCZ and 9% personality disorders (Shantna et al., 2009).
Such comorbidity is associated with an increase of severity for all dis-
orders, although it is unclear whether this relationship is causal or the
result of shared genetic and/or environmental risk factors. Some studies
have started to inspect these relationships using both genetic correla-
tion and polygenic risk score approaches, supporting the hypothesized
role of shared genetic risk factors in the lifetime co-occurrence of sev-
eral psychiatric disorders and SUD (Carey et al., 2016; Du Rietz et al.,
2017; Hartz et al., 2017; Reginsson et al., 2018).
Here we performed a GWAS meta-analysis of cocaine dependence in
samples with European ancestry using datasets from the dbGaP re-
pository. Then we investigated the shared genetics between cocaine
dependence and other psychiatric traits.
2. Experimental procedures
Detailed description of the materials and methods used, as well as
supplementary figures, can be found in the Supplementary Information.
2.1. Subjects
The case-control GWAS meta-analysis was performed using four
datasets from the dbGaP repository (https://www.ncbi.nlm.nih.gov/
gap) under the project 17,170 (Table 1). All cases used met DSM-IV
criteria for cocaine dependence, although most of them are also de-
pendent to other drugs of abuse. Diagnoses for schizophrenia, bipolar
affective disorder or other major psychotic illnesses or gross cognitive
impairment were exclusion criteria for all samples except for SAGE.
Drug abuse or dependence were discarded only in controls of the SAGE
sample, whereas in the other studies general population individuals
were used as controls (see Supplementary Information for detailed
description of subjects used in this study).
Since samples 2–4 did not have enough controls to perform the
association studies, we used controls from other datasets, strategy
previously followed by others (Johnson et al., 2016). In all cases, pa-
tients and controls were from the same geographic area, they were
genotyped with the same array and using the same genome assembly. In
order to reduce bias, we merged controls with cases prior to quality
control (QC) and imputation (Mitchell et al., 2014; Uh et al., 2012). The
analyses performed to control for population stratification is summar-
ized in Fig. S1.
The study was approved by the ethics committee of our institution,
in accordance with the Helsinki Declaration and with the dbGaP pro-
tocols.
2.2. Quality control and association analyses
Prior to analysis, stringent QC was performed on the genotyped
markers and individuals in each sample using the standardized pipeline
“Ricopili” (Ripke, 2014). Very briefly, subjects and SNPs were selected
according to “Ricopili” default parameters: SNP and subject call
rate > 0.98, SNP Hardy-Weinberg equilibrium (P > 1e−06 in con-
trols or P > 1e−10 in cases), autosomal heterozygosity deviation
(|Fhet| < 0.2) and sex check based on X chromosome heterozygosity.
European-ancestry individuals were selected based on principal com-
ponent analysis (PCA): PC1 and PC2 were used to define a genetic
homogenous population, excluding individuals with PC values greater
than three standard deviations from the reference population (Eur-
opean individuals from 1000 Genomes Project Phase 3 (1KGP3)). Re-
lated individuals and genetic outliers were excluded. A permutation test
for between-group IBS differences with fixed 10,000 permutations was
performed to discard population stratification between cases and con-
trols (T1 p-value<0.05).
After QC, non-genotyped markers were imputed using the European
individuals from the 1KGP3 reference panel in MINIMAC3 (https://
genome.sph.umich.edu/wiki/Minimac3).
In order to identify overlapping or related individuals across all
datasets, we ran the “Ricopili” PCA module considering the four sam-
ples together, and one individual of each pair was excluded.
For each sample, case-control GWAS was conducted using logistic
regression under the additive model in PLINK v1.9 (http://pngu.mgh.
harvard.edu/purcell/plink/). The 10 firsts PCs were included as cov-
ariates to correct for population stratification, and only variants with
imputation INFO score > 0.8 and minor allele frequency
(MAF)>0.01 were considered. In all samples the genomic inflation
factor (λ) was lower than 1.05.
2.3. GWAS meta-analysis
In total, 2085 cases and 4293 controls were meta-analyzed using an
inverse-variance weighted fixed effects model in METAL (http://csg.
sph.umich.edu//abecasis/Metal/)(Willer et al., 2010). Association re-
sults were considered only for variants with an effective sample size
[N=2/((1/Ncases)+ (1/Ncontrols))]> 70% of the full meta-analysis.
Heterogeneity across studies was tested with the Cochran's Q test and
quantified with the I2 heterogeneity index, implemented in METAL.
Manhattan plot and Q-Q plot from each sample and the meta-ana-
lysis results were generated with the library “qqman” implemented in
R.
2.4. LD score intercept evaluation
LD score (LDSC) regression analysis was used to calculate LDSC
intercept by regressing the chi-square statistics from GWAS against LD
scores for each SNP (downloaded from GitHub website, https://github.
com/bulik/ldsc) (Bulik-Sullivan et al., 2015b).
2.5. SNP heritability
The proportion of phenotypic variance explained by common SNPs
Table 1
Description of dbGaP samples used in the cocaine dependence GWAS meta-analysis.
Sample N cases %F cases N controls %F controls Genotyping chip dbGaP code
Sample 1 (SAGE) 468 39.3% 1284 69.9% Illumina ILMN_Human-1 phs000092.v1.p1 (cases/controls)
Sample 2 609 45.9% 410 50.2% Illumina HumanOmni1-Quad_v1-0_B phs000952.v1.p1 (cases/controls) + phs000179.v5.p2 (controls)
Sample 3 504 44.3% 1190 62% Illumina Human660W-Quad_v1_A phs000277.v1.p1 (cases/controls) + phs000170.v2.p1 (controls)
Sample 4 504 36.7% 1409 41.9% Illumina HumanOmni1-Quad_v1-0_B phs000425.v1.p1 (cases/controls) + phs000524.v1.p1 (controls)
Total 2085 4293
%F=percentage of females
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in the liability scale was assessed using two different methodologies:
LDSC 1.0.0 (https://github.com/bulik/ldsc/) and the Genome-based
REstricted Maximum Likelihood analysis implemented in the tool
Genome-wide Complex Trait Analysis (GCTA-GREML; https://
cnsgenomics.com/software/gcta/#Overview) (Lee et al., 2011). In
both analyses, a population prevalence for cocaine dependence of 1.1%
was considered (Compton et al., 2007). The GCTA-GREML analysis was
adjusted for the 10 first PCs and a dummy variable indicating geno-
typing-study.
Partitioned heritability analysis was performed using LDSC 1.0.0
based on 24 functional overlapping annotations described previously
(Finucane et al., 2015). Enrichment in the heritability of a functional
category was defined as the proportion of SNP heritability explained
divided by the proportion of SNPs. The threshold for significance was
calculated using the Bonferroni correction for multiple testing (P < 2e-
03).
2.6. Functional annotation of risk SNPs
SNPs were functionally annotated using FUMA (http://fuma.ctglab.
nl/)(Watanabe et al., 2017). FUMA define lead SNPs as signals that are
significantly associated with the phenotype of interest (we considered
suggestive associations (P < 1e-05)) and independent to each other
(r2 < 0.1). For each lead SNP, a “Genomic risk locus” is defined, in-
cluding all independent signals that are physically close or overlapping
in a single locus. The variants located in a “Genomic risk locus” were
explored considering the following functional annotations: eQTL (from
GTEx v6/v7 and BRAINEAC), CADD_v1.3, ANNOVAR, Reg-
ulomeDB_v1.1, 15-core chromatin state and GWAS-catalog e91.
2.7. Gene-based and gene-set association analyses
Gene-based and gene-set association analyses were performed with
MAGMA 1.05b (Willer et al., 2010) using the summary statistics from
the cocaine dependence GWAS meta-analysis. For gene-based analysis,
the SNP-wise mean model was used as the statistic test, considering p-
values for SNPs located within the transcribed region. For multiple
testing corrections, 10% False Discovery Rate (FDR) was considered.
Gene-set analysis was used to test for enrichment in association
signals in genes belonging to specific biological pathways or processes.
We performed a competitive test using: “All Canonical Pathways” (1329
gene sets), “GO” (4436 gene sets) and “BioCarta” (217 gene sets) pro-
vided by MsigDB 5.1 (https://software.broadinstitute.org/gsea/
msigdb/)(Subramanian et al., 2005). Multiple testing corrections were
applied to each gene set separately. When gene sets are strongly over-
lapping, the Bonferroni correction can be quite conservative, and for
that reason, we used an empirical multiple testing correction im-
plemented in MAGMA, based on a permutation procedure.
2.8. Shared genetic factors between cocaine dependence and comorbid
conditions
2.8.1. Subjects
We studied shared genetic factors between cocaine dependence and
six previously described comorbid conditions using publicly available
GWAS summary statistics of SCZ, ADHD, MDD, children's aggressive
behavior, antisocial behavior and risk-taking behavior (Table 2).
Summary statistics from the vitamin D levels GWAS of the UK Biobank
was used as a negative control.
2.8.2. LDSC genetic correlation
Genetic correlation between cocaine dependence and the six se-
lected comorbid disorders/traits was calculated using LDSC 1.0.0
(Bulik-Sullivan et al., 2015a). Summary statistics from all samples and
pre-computed LD scores from HapMap3_SNPs calculated on 378 phased
European-ancestry individuals from 1KGP3 were used (available at Ta
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https://github.com/buligk/ldsc). After Bonferroni correction, the sig-
nificance threshold was adjusted to P < 7.1e-03.
Furthermore, the genetic correlation of cocaine dependence with
other traits available at LD Hub (http://ldsc.broadinstitute.org/ldhub/)
(Zheng et al., 2017) was evaluated (Bonferroni correction threshold
P < 7.2e-05).
2.8.3. Polygenic risk scores for cocaine dependence
Poligenic risk score (PRS) analysis was performed using the PRSice
2.1.0 software (https://github.com/choishingwan/PRSice) (Euesden
et al., 2015).
The four cocaine dependence datasets were merged using PLINK
v1.9 and used as a target sample. After merging, strict QC was applied
resulting in 5,957,307 SNPs in 2083 cases and 4287 controls. To assess
population stratification PCA was performed, and the 10 first PCs and a
dummy variable indicating genotyping-study was included in the PRS
analysis as a covariate.
Summary statistics of the seven phenotypes described above were
used as discovery samples, which were clumped (r2 < 0.1 in a 250-kb
window) to remove SNPs in linkage disequilibrium (LD). Then, PRSs
were estimated for each discovery sample using a wild range of meta-
analysis p-value thresholds (PT) between PT=1e-04 and PT=1 at in-
crements of 5e-05. For each PT, the proportion of variance explained
(R2) by each discovery sample was computed by comparing the full
model (PRS+ covariates) score to a reduced model (covariates only).
The reported R2 value is the difference between R2 from the two
models. For quantitative traits we performed linear regression analysis,
and for qualitative traits we used logistic regression and Nagelkerke's
pseudo-R2 values are shown.
As recommended, we used the significance threshold of P=0.004
(Euesden et al., 2015). Bonferroni correction was applied considering
the seven tested phenotypes (P < 5.7e-04).
3. Results
3.1. GWAS results
We performed a GWAS meta-analysis of cocaine dependence using
four datasets from the dbGaP repository. In total, we meta-analized
9,290,362 common genetic variants in 2085 cases and 4293 controls of
European ancestry. No marker demonstrated significant heterogeneity
between studies (Fig. S2 and Table S1). The Q-Q plot (Fig. 1A) dis-
played a λ of 1.06, comparable to other GWAS. The LDSC analyses
estimated an intercept of 1.01 (SE=0.006; P=0.1), not sig-
nificantly> 1, discarding residual population stratification or cryptic
relatedness (Bulik-Sullivan et al., 2015b).
None of the analyzed variants reached the threshold for genome-
wide significance (P < 5e-08) in the SNP-based analysis, although we
identified several suggestive associations (P < 1e-05) (Table S1;
Fig. 1B).
3.2. Polygenic architecture of cocaine dependence
We applied two approaches to assess the proportion of phenotypic
variance explained by common SNPs. For LDSC, the estimated SNP
heritability in liability scale was h2snp= 0.30 (SE= 0.06; P=2.4e-07),
and for GCTA-GREML h2snp= 0.27 (SE=0.03, P < 0.01). Then we
performed partitioned heritability analysis on LDSC based on functional
genomic categories and found significant enrichment in the heritability
by SNPs located in intronic regions (enrichment= 2.17; SE= 0.45;
P=1.2e-03), and a nominal result for conserved genomic regions
(enrichment= 23.63; SE=8.57; P=4e-03) (Fig. S3).
3.3. Functional annotation of risk SNPs
To identify potentially interesting regions with FUMA we
considered the SNPs showing suggestive associations (P < 1e-05), as
the SNP-based analysis did not reveal genome-wide significant hits
(P < 5e-08). We identified 23 lead SNPs which correspond to 22
genomic risk loci including 112 genes (Table 3). Interestingly, the risk
locus located on chromosome 6 overlaps with a genomic region pre-
viously associated with schizophrenia. This region is defined by two
lead SNPs (rs806973 and rs56401801, GWAS P=3.1e-06 and 3.4e-06,
respectively) and it includes 77 genes and 458 nominally associated
SNPs. Moreover, most of the SNPs in this region (447) are brain eQTLs
for at least one member of a small group of 12 genes, including
BTN3A2, HIST1H2AK, ZSCAN31, PRSS16 and ZNF184 (Figs. 2 and S4).
3.4. Gene-based and gene-set analyses
The gene-based analysis mapped 3,418,270 SNPs from the GWAS
meta-analysis to 18,069 protein-coding genes (Fig. S5 and Table S2).
The HIST1H2BD gene, located in a genomic region on chromosome 6
that showed a suggestive association in the SNP-based analysis, dis-
played a significant gene-wise association with cocaine dependence
(10% FDR), although it did not overcome the Bonferroni correction for
multiple testing. Then we performed competitive gene-set tests for all
BioCarta, GO and Canonical Pathways. No gene sets attained a sig-
nificant association with cocaine dependence after correction for mul-
tiple testing (Tables S3–5), although the BioCarta immunity pathway
“BIOCARTA TNFR2 PATHWAY” showed a trend (uncorrected
P= 5.38e-04, corrected P= 0.09), being also the most significantly
associated canonical pathway gene set. Furthermore, from the 10 GO
gene sets with lower p-values, seven were related to synapse organi-
zation, glutamatergic neurotransmission and brain functions.
3.5. Cocaine dependence and shared genetic factors with comorbid
conditions
Cocaine dependence is highly comorbid with other psychiatric dis-
orders like SCZ, ADHD and MDD, and also with other phenotypes like
aggressive behavior in children, antisocial behavior or risk taking. In
order to investigate whether these phenotypic correlations are geneti-
cally mirrored, we performed a genetic correlation analysis using LDSC
analysis and found significant genetic correlations (P < 7.1e-03) be-
tween cocaine dependence and SCZ (rg= 0.2; SE=0.05; P=1e-04),
ADHD (rg= 0.5; SE=0.08; P=1.6e-09), MDD (rg=0.4; SE=0.08;
P=6.6e-07) and risk taking (rg= 0.35; SE= 0.06; P=9.1e-08)
(Fig. 3A). No significant correlations were found with children's ag-
gression or antisocial behavior, nor with a negative control (Vitamin D
levels).
On the other hand, we tested genetic correlations between cocaine
dependence and all the GWAS summary statistics publicly available in
the LD Hub. From the 690 tested traits, 109 demonstrated significant
correlations after applying the Bonferroni correction for multiple
testing, including negative correlations with educational achievements
(e.g. college completion) or with reproductive traits (e.g. age at first
child) and positive correlations with familiar situation (e.g. tobacco
smoke exposure at home) or with several psychological or psychiatric
traits like neuroticism, depressive symptoms or loneliness (Fig. S6 and
Table S6). The high number of significant associations may be ex-
plained by the high redundancy of the phenotypes of the LD Hub.
We also investigated the shared genetic etiology between cocaine
dependence and comorbid phenotypes through PRS analysis, and tested
whether these phenotypes are associated with cocaine dependence
status. For all the discovery samples tested, PRS was significantly as-
sociated with cocaine dependence: SCZ (pseudo-R2= 2.28%,
PT= 0.4911, P=1.21e-26), ADHD (pseudo-R2= 1.39%,
PT= 0.04275, P=4.5e-17), antisocial behavior (pseudo-R2= 1.33%,
PT= 0.4055, P=2.2e-16), MDD (pseudo-R2= 1.21%, PT=0.0129,
P=4.35e-15), risk taking (R2= 0.60%, PT= 0.00135, P=2.7e-08)
and children's aggressive behavior (R2= 0.30%, PT=0.3552,
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P=8.8e-05) (Figs. 3B and S7). In all cases, the quantile plot shows the
positive nature of this relationship as cocaine dependence increases
with greater polygenic load at each discovery dataset (Fig. S8). As ex-
pected, the negative control based on vitamin D levels was not asso-
ciated with cocaine dependence (R2= 0.07%, PT=0.03075,
P=0.06).
4. Discussion
To our knowledge, this is the largest GWAS meta-analysis on co-
caine dependence performed so far in individuals with European an-
cestry, although the sample size is still limited. No genome-wide sig-
nificant (GWS) signals emerged from the SNP-based analysis, but the
gene-based study identified HIST1H2BD as significantly associated with
cocaine dependence. This gene is located in a region of chromosome 6
enriched in immune system and histone-related genes. These pathways
Fig. 1. Results from the GWAS meta-analysis on cocaine dependence. A) Q-Q plot and B) Manhattan plot. Red line: threshold for genome-wide significance (P < 5e-
08). Blue line: threshold for suggestive associations (P < 1e-05). (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
Table 3
FUMA analysis of genetic risk loci for cocaine dependence as identified from the GWAS meta-analysis.
Genomic locus Positiona Lead SNP SNP position GWAS P-value nSNPs nGenes Genes
1 chr1:15,916,714–16,049,893 rs148069235 15,950,064 9.52e-06 236 6 DNAJC16, AGMAT, DDI2, RSC1A1,
PLEKHM2, SLC25A34
2 chr1:104,966,872–104,966,872 rs72685414 104,966,872 1.87e-06 1 0
3 chr3:50,615,472–51,356,217 rs148179194 50,798,652 7.03e-06 152 3 C3orf18, HEMK1, DOCK3
4 chr3:84,862,871–84,961,810 rs6767407 84,955,841 9.61e-06 27 0
5 chr3:172,170,104–172,214,001 rs57361543 172,212,144 5.09e-06 28 2 GHSR, TNFSF10
6 chr4:82,943,149–83,005,137 rs7675557 82,970,816 2.28e-06 16 1 RASGEF1B
7 chr4:117,560,979–117,607,439 rs67769911 117,607,070 6.33e-06 18 1 MIR1973
8 chr5:30,884,915–31,001,774 rs62357000 30,884,915 9.20e-06 4 1 CDH6
9 chr5:44,051,305–44,130,776 rs4410642 44,129,423 9.42e-06 61 0
10 chr5:54,436,897–54,754,893 rs334878 54,519,878 7.67e-06 90 9 ESM1, CDC20B, GPX8, MCIDAS, CCNO,
DHX29, SKIV2L2, PLPP1, DDX4
11 chr5:106,788,817–106,796,026 rs71575441 106,788,817 2.37e-06 2 1 EFNA5
12 chr6:26,148,326–28,301,195 rs806973;
rs56401801
26,148,326;
27,301,762
3.14e-06;
3.44e-06
458 77 Locus too broad
13 chr8:99,193,765–99,226,821 rs4734387 99,193,765 4.20e-06 35 1 NIPAL2
14 chr9:28,890,331–28,993,271 rs35735220 28,963,289 6.86e-06 113 0
15 chr9:118,176,789–118,273,407 rs10121366 118,244,022 7.33e-06 54 0
16 chr13:36,947,826–37,019,186 rs79309473 36,972,202 1.89e-06 26 5 SOHLH2, SPG20, SPG20-AS1, CCNA1,
SERTM1
17 chr13:88,150,884–88,150,884 rs7332726 88,150,884 7.10e-06 1 0
18 chr16:6,654,017–6,695,032 rs112252907 6,675,141 4.43e-06 42 1 RBFOX1
19 chr16:84,581,684–84,590,225 rs247831 84,581,893 9.17e-06 8 2 TLDC1, COTL1
20 chr18:43,206,985–43,231,622 rs1484873 43,206,985 4.45e-06 14 1 SLC14A2
21 chr18:73,743,937–73,775,398 rs73973283 73,757,906 6.46e-06 88 0
22 chr20:54,516,338–54,516,338 rs11086525 54,516,338 3.01e-06 1 0
a Gene coordinates based on GRCh37/hg19. NSNPs: Number of nominally associated SNPs per genomic locus.
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have previously been associated with other psychiatric disorders like
schizophrenia, major depressive disorder and bipolar disorder
(O'Dushlaine, 2015). Despite the lack of GWS findings in this region, we
identified many subthreshold variants. Based on the omnigenic model
that has recently been proposed for complex disorders, these variants
could point at regulatory elements of core genes (Boyle et al., 2017;
Wray et al., 2018) and, therefore, contribute to the susceptibility to
cocaine dependence, as most of them are brain eQTLs. Interestingly,
this region overlaps with the genomic region that has been most con-
sistently associated with schizophrenia. Indeed, it contains five SNPs
(rs16897515, rs17693963, rs34706883, rs41266839 and rs55834529)
nominally associated with cocaine dependence (P < 1e-04) that had
previously been associated with schizophrenia and with bipolar dis-
order, being the risk allele the same in all studies. The genetic variant
most consistently associated with schizophrenia is rs17693963, re-
ported in five different studies (Bergen et al., 2012; Ripke et al., 2011;
2014; Ruderfer et al., 2014; Sleiman et al., 2013), which is a brain eQTL
for PRSS16, ZSCAN9, ZNF184 and ZSCAN31. Furthermore, a tran-
scriptomic study performed in lymphoblastoid cell lines of 413 in-
dividuals with schizophrenia and 446 controls found that the top dif-
ferentially expressed genes are located in this region (e.g. HIST1H2BD,
HIST1H2BC, HIST1H2BH, HIST1H2BG and HIST1H4K) (Sanders et al.,
2013).
Cocaine dependence is a highly heritable disorder (around 65–79%
(Ducci and Goldman, 2012)). Our analyses estimate that SNPs sig-
nificantly capture more than one third of cocaine dependence herit-
ability, as estimated using two different methods (LDSC h2SNP= 0.30;
GCTA-GREML h2SNP= 0.27). Interestingly, studies with comparable
sample sizes obtained similar results for cocaine dependence
(h2TOTAL= 0.65–0.79; h2SNP= 0.28) (Huggett and Stallings, 2019), al-
cohol dependence (h2TOTAL= 0.55–0.69; h2SNP= 0.33) (Mbarek et al.,
2015) and for other psychiatric disorders like ADHD
(h2TOTAL= 0.77–0.88; h2SNP= 0.28) and schizophrenia
(h2TOTAL= 0.7–0.8; h2SNP= 0.28) (Cross-Disorder Group of the PGC
et al., 2013). Increasing sample size has resulted in lower SNP-herit-
ability estimates in some studies (e.g. alcohol dependence, h2SNP= 0.09
(Walters et al., 2018) and MDD, h2SNP= 0.12 (Wray et al., 2018)), but in
others they remained similar (e.g. schizophrenia, h2SNP= 0.26 (Ripke
et al., 2014) and ADHD, h2SNP= 0.22 (Demontis et al., 2019)). For this
reason, larger samples are needed to confirm our results.
It is well known that most psychiatric disorders are highly co-
morbid. About 73.4% of cocaine abuse/dependence patients have co-
morbid mental disorders: 49.7% have personality disorders (e.g. 5.3%
schizoid and 17% antisocial personality) and 61.5% other mental dis-
orders (e.g. 23.4% MDD and 20.5% anxiety) (Arias et al., 2013).
However, the reasons for these covariations remain largely unknown.
We investigated whether the phenotypic correlations between cocaine
dependence and six comorbid psychiatric traits are genetically mirrored
by performing genetic correlation analyses using LDSC. For the first
time we found significant genetic correlation with ADHD, SCZ, MDD
and risk-taking behavior, although these results should be taken with
caution and need to be followed up in a larger sample of cocaine-de-
pendent individuals. Furthermore, we used the PRS method that, in
contrast to LDSC, uses individual-level SNP data, resulting in higher
statistical power and allowing for direct testing of interaction effects.
According to our results, all the tested comorbid conditions are asso-
ciated with cocaine dependence status, suggesting that cocaine de-
pendence is more likely in individuals with many risk alleles for the
tested conditions than in those with fewer risk alleles. To our knowl-
edge, this is the first report of a shared genetic etiology between cocaine
dependence and ADHD, antisocial behavior, risk-taking behavior and
children's aggressive behavior based on genome-wide data. Previous
Fig. 2. Circo-plot from genomic risk loci on chro-
mosome 6 by FUMA. The most outer layer is the
Manhattan plot (only SNPs with P < 0.05 are dis-
played). SNPs in genomic risk loci are colour-coded
as a function of their maximum r2 to the lead SNPs in
the locus, as follows: red (r2 > 0.8), orange
(r2 > 0.6), green (r2 > 0.4), blue (r2 > 0.2) and
grey (r2≤ 0.2). The rs ID of the top SNPs in the risk
locus is displayed in the most outer layer. Y-axis is
ranged between 0 to the maximum -log10(p-value) of
the SNPs. The second layer is the chromosome ring,
with the genomic risk locus highlighted in blue. Here
genes are mapped by chromatin interactions (or-
ange) or eQTLs (green). When the gene is mapped by
both, it is colored in red. (For interpretation of the
references to colour in this figure legend, the reader
is referred to the web version of this article.)
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studies have reported significant PRS associations between cocaine
dependence and SCZ or MDD (Carey et al., 2016; Hartz et al., 2017;
Reginsson et al., 2018), and also between SUD and other psychiatric
disorders (Du Rietz et al., 2017; Gurriarán et al., 2018), although our
study used the largest sample of cocaine dependence for this type of
analysis so far. This correlation can reflect biological pleiotropy, where
similar genetic mechanisms influence more than one trait, or mediated
pleiotropy, where one phenotype is causally related to a second phe-
notype, so that the variants associated with this phenotype are in-
directly associated with the second one. A recent study performed a
GWAS meta-analysis of eight psychiatric disorders, and found that 75%
of the LD-independent associated regions (109 out of 146) were asso-
ciated with more than one disorder (Cross-Disorder Group of the PGC
et al., 2019). Supporting the idea that the high comorbidity of psy-
chiatric disorders can be explained, in part, because some of the genetic
risk factors are shared among them (Brainstorm Consortium et al.,
2018; Martin et al., 2018).
An important and controversial consideration in association studies
for substance dependence is the selection of the control sample. Some
studies use control individuals that have been exposed to the drug at
least once (Agrawal et al., 2018; Gelernter et al., 2014). In this case, the
association study would capture the predisposing genetic component
involved in the transition from use to addiction, but not the ones related
to the initiation in the consumption (e.g. impulsivity or risk-taking
behavior). Our study shows evidence of shared genetic risk factors
between cocaine dependence and risk-taking behavior, estimating a
high genetic correlation (rg= 0.35) and identifying a significant asso-
ciation also in the PRS analysis. For the above reasons, we have used
unscreened controls from the general population in our study (except
for the SAGE controls, where dependence was discarded). It is also true
that this approach could eventually dilute positive findings due to the
presence of some cases in the control sample. However, based on the
prevalence of cocaine dependence in the general population (about
1.1%), the probability of false negative results due to this effect is low.
Similar controls were used in other GWAS of drug addiction (Ikeda
et al., 2013; Johnson et al., 2016).
This study has strengths and limitations that need some discussion.
We performed a GWAS meta-analysis using all the cocaine dependence
datasets available at the dbGaP repository, but we could not find any
GWS association at the SNP-based level, as expected given the limited
sample size, with a total of around 6000 subjects, one third of them
cases. However, these data allowed us to detect genetic correlations
between cocaine dependence and several co-occurring conditions. Also,
we calculated polygenic risk scores that explain a small fraction of the
variance in the target phenotype, with figures that are similar to those
obtained for other pairs of psychiatric conditions. To obtain a more
comprehensive picture of the etiological overlap between cocaine de-
pendence and comorbid conditions, larger studies will be needed, and
other genetic factors should be included in the analyses (e.g. CNVs and
rare variants). It is important to note that the high comorbidity across
the tested traits could influence our results on genetic correlation and
PRS. However, several studies have shown that this high co-occurrence
is due, at least in part, to shared genetic risk factors (Brainstorm
Consortium et al., 2018; Martin et al., 2018). On the other hand, some
of the dbGaP datasets used included only cases but not control in-
dividuals. For this reason, we used controls from other datasets that can
introduce potential biases into the experimental design. Nevertheless,
we performed very strict quality controls to avoid population stratifi-
cation: the paired case and control samples were genotyped with the
same platform and are from the same geographical area, the merging of
the different datasets was performed prior to quality control and im-
putation, and after that a permutation test was performed to discard
population stratification (Mitchell et al., 2014). Population admixture is
one of the main sources of false positive findings in association studies.
For this reason, we performed ancestry selection using genetic data,
which allowed us to discard a relatively high number of individuals
with non-European ancestry (ranging from 8 to 30% depending on the
dataset). This highlights the importance of using genetic data rather
than self-reported ancestry, as previously discussed by others (Shraga
et al., 2017). Moreover, the LDSC analyses confirmed that most of the
observed inflation (λ =1.06) can be attributed to polygenicity rather
than to residual population stratification or cryptic relatedness (Bulik-
Sullivan et al., 2015b). Finally, the disease phenotype has not been
excluded in most of the control samples, which may potentially dilute
positive findings in the association study (but not lead to false positive
results).
5. Conclusion
In conclusion, we reported the largest cocaine dependence GWAS
meta-analysis on individuals of European ancestry, even though no
GWS hits could be identified. Enlarging the sample size of this study
would increase the chances to detect significant associations. However,
the fact that our analyses highlighted a region on chromosome 6 that
also pops-up in several schizophrenia GWAS supports the idea of shared
genetic risk factors in these two comorbid disorders. This is in line with
the significant results derived from the genetic correlation and PRS
analyses in our study and in others. Finally, it would also be interesting
to investigate the genetic pathways and neurobiological mechanisms
that underlie the genetic overlap between cocaine dependence and
comorbid traits.
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